IBC Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for T-cell redirecting bispecific antibodies for treatment of disease (US 10,308,688) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Feb 20, 2027The maintenance fee for Murine, Chimeric, Humanized or Human Anti-TNF-alpha Antibodies (US 10,385,139) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for T-cell redirecting bispecific antibodies for treatment of disease (US 9,315,567) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,597,659 | Tetrameric cytokines with improved biological activity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,457,072 | Dock-and-lock (DNL) vaccines for cancer therapy In force · From the USPTO record | In force | From the USPTO record | |
| US 9,315,567 | T-cell redirecting bispecific antibodies for treatment of disease In force · From the USPTO record | In force | From the USPTO record | |
| US 9,382,329 | Disease therapy by inducing immune response to Trop-2 expressing cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,670,286 | Disease therapy by inducing immune response to Trop-2 expressing cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,682,143 | Combination therapy for inducing immune response to disease In force · From the USPTO record | In force | From the USPTO record | |
| US 9,879,088 | Disease therapy by inducing immune response to Trop-2 expressing cells In force · From the USPTO record | In force | From the USPTO record | |
| US 10,111,954 | Combination therapy for inducing immune response to disease In force · From the USPTO record | In force | From the USPTO record | |
| US 10,131,712 | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,183,992 | T-Cell Redirecting Bispecific Antibodies for Treatment of Disease In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 19: 5 lapsed for an unpaid fee · 49 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 abandoned · 12 no status recorded